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ABSTRACT 
 Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the central nervous 
system leading to debilitating long-term neurologic damage, primarily due to axonal loss 
following unsuccessful remyelination and the limited ability to remyelinate in the adult human 
brain. This review summarizes the current knowledge regarding combined administration of 
Cuprizone (CPZ) and rapamycin as a novel animal model for MS. Utilization of CPZ induces 
non-immune mediated demyelination, therefore bypassing complexities of the immune system 
and allowing analysis of de-/remyelination. Furthermore, remyelination occurs simultaneously 
with demyelination due to ongoing oligodendrocyte progenitor cell (OPC) differentiation into 
mature oligodendrocytes (OLGs).  
 The immunosuppressive agent, rapamycin inhibits the regulatory pathway Akt/mTOR, 
which primarily controls myelination. This inhibition prevents ongoing OPCs from 
differentiating into mature oligodendrocytes (OLGs), therefore preventing myelination. The dual 
CPZ/rapamycin model produces more complete demyelination and a slowed remyelination 
phase. The long-term relevance of this review is to assess distinct stages and contributors of de-
/remyelination in MS to better assess possible therapeutics for patients diagnosed with 
demyelinating diseases, such as MS.  
 
INTRODUCTION 
 Multiple Sclerosis (MS) is an autoimmune demyelinating disease of the central nervous 
system (CNS). Myelin is a fatty substance composed of proteins and phospholipids that surround 
nerve fibers. Myelination of these nerve fibers are essential for facilitation of signal conduction 
and for supporting neuroglia in the axonal environment, two examples of which are, microglia 
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and astrocytes (Matsushima et al., 2001). Loss of myelin, also called demyelination, leads to 
debilitating neurological consequences ranging from motor related symptoms (loss of balance 
and loss of speech, loss of sight, muscle spasms, fatigue, weakness, bowel and bladder 
incontinence), and cognitive impairments (anxiety and memory loss) to in rare cases, seizures 
(Praet et al. 2014).  
 The etiology of MS is unknown and there is no cure for the disease. A recent study 
estimated that the number of people diagnosed with MS worldwide has increased from 2.1 
million in 2008 to 2.3 million in 2013. In addition to having rising prevalence rates, MS is also 
classified as one of the world’s most common neurologic disorders and one of the leading causes 
of non-traumatic neurologic disabilities in young adults (Browne and Chandraratna, 2014). 
 Current animal models of MS do not provide a complete de-/remyelination time frame in 
which to assess therapeutics, such as dietary supplementation. Based on the findings of this 
review, future therapeutic studies may utilize the CPZ/rapamycin model.  
 
CURRENT MODELS FOR MULTIPLE SCLEROSIS 
 Animal models of demyelination have served as a primary resource in the ongoing effort 
to understand the molecular and cellular mechanisms responsible for demyelinating diseases 
such as MS. The two most commonly used models of demyelination are experimental 
autoimmune encephalomyelitis (EAE) and toxically induced demyelination via cuprizone.  
 Experimental autoimmune encephalomyelitis presents the organism with an 
immunization containing components from the CNS. These components may include myelin 
basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), or proteolipid protein (PLP), 
all of which target myelin via antigen presentation and autoimmunity (Nathoo et al., 2014). The 
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EAE model has been used for many years and led to the development of many therapies; 
however, it’s effects vary depending on animal strain, age, and duration of treatment. This 
variability makes it difficult to analyze mechanisms contributing towards de-/remyelination 
(Sachs et al., 2014). The EAE model is also characterized by varied lesion localization. These 
asynchronous lesions lack anatomical reproducibility between organisms making the model 
difficult to reproduce and quantify (Matsushima et al., 2001; Sachs et al., 2014). EAE induces an 
inflammatory immune response that leads to the compromise of the blood-brain-barrier (BBB) 
and infiltration of external T cells and other immune cells. Normally, these immune cells cannot 
pass the BBB. In the attempt to assess distinct stages of de-/remyelination, a more reliable model 
of demyelination would separate the two phases, in order to fully assess remyelination from 
completely demyelinated regions,  
 The second model induces demyelination toxically via cuprizone (CPZ) [oxalic acid 
bis(cyclohexylidene hydrazide)]. CPZ is a cooper-chelating agent added as a supplement to 
rodent chow that induces demyelination throughout the telencephalon. The majority of 
demyelination associated with CPZ occurs in the caudal regions of the corpus callosum (CC), 
hippocampus, and superior cerebellar peduncles (Nathoo et al., 2014).  
 In this model, acute demyelination is induced in 8-10 week old C57BL/6 mice via 
administration of CPZ-supplemented diet for 5-6 weeks. Commencement of 0.2% CPZ at this 
age provides synchronous, reproducible, and largely reversible patterns of demyelination while 
minimizing detrimental systemic effects, such as toxicity of the liver. If treatment is maintained 
for 14+ weeks detrimental effects are observed throughout the organism, such as disturbances to 
mitochondrial function in the brain and liver. Death of the mice is commonly reported at 16 
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weeks of treatment. This length of treatment is classified as “chronic demyelination” and is not 
completely reversible (Matsushima & Morell, 2001). 
 At three weeks of acute CPZ-induced demyelination myelin genes encoding mRNA for 
MBP, myelin associated glycoproteins (MAG), and ceramide galactosyltransferase (CAG) are 
quantifiably reduced (Bosio et al., 1996). An increase in microglia/macrophage levels and 
ongoing OPC differentiation coincide with a decrease in myelin mRNA translation. By 4 weeks 
of treatment, OPC and astrocyte levels surge (Praet et al., 2014). Meanwhile, CPZ continuously 
induces demyelination throughout the brain. After 5 weeks of treatment there is almost complete 
depletion of mature OLGs in the caudal regions of the CC and superior cerebellar peduncles. By 
4-5 weeks a substantial amount of axons are demyelinated throughout the caudal regions of the 
CC and superior cerebellar peduncles (Matsushima et al., 2001; Thiessen et al., 2013). 
Remyelination starts in earnest immediately after CPZ removal, and within the first week of 
recovery numerous remyelinated axons appear in the medial CC. This suggests that 
remyelination ensues rapidly after CPZ removal, due to ongoing OPC proliferation into mature 
OLGs (Gudi et al., 2014).  
 Both the EAE and CPZ models can be used to model demyelination and to test the 
efficacy of certain drugs and treatment methods; however, the EAE model exhibits asynchronous 
lesions that are difficult to reproduce. Furthermore, the CPZ model exhibits varying 
demyelination based on mouse strain, age, and gender,, ongoing remyelination during CPZ 
treatment preventing complete demyelination and rapid axonal remyelination following CPZ 
cessation In the attempt to evaluate remyelinating therapeutics, rapid remyelination makes these 
assessments difficult  to perform and interpret. Utilization of rapamycin, an Akt/mTOR inhibitor, 
in conjunction CPZ prevents remyelination during CPZ administration and exhibits more 
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complete demyelination compared to CPZ treatment alone. Inhibition of differentiating OPCs via 
rapamycin yields an elongated remyelination phase. While the CPZ and EAE animal models may 
mimic the demyelinating effects of MS, the combined treatment of CPZ/rapamycin presents a 
targeted model to assess remyelinating therapeutics by separating the de-/remyelination phases 
through Akt/mTOR inhibition, furthermore inhibiting OPC differentiation during the 
remyelination phase. (Sachs et al., 2014).  Inhibition of ongoing remyelination during CPZ 
treatment via rapamycin would exhibit a significant amount of reproducible demyelination in 
specific regions of the CC (Tagge et al., 2016).  Ample demyelination in these regions would 
allow for remyelinating therapeutics to be manipulated and quantified through in-vivo imaging 
techniques throughout the recovery phase without additional drug administration. Throughout 
the uninterrupted recovery phase, quantification of axonal remyelination would allow for 
targeted therapeutics to be assessed in specific regions that previously exhibited a considerable 
level of demyelination.   
 
ROLE OF REGULATORY T CELLS IN MULTIPLE SCLEROSIS 
 Theories have attributed the origin of MS to genetic and environmental factors, with the 
most likely being immune dysregulation. The primary role of the immune system is to attack and 
eliminate foreign antigens that may be acquired genetically and/or environmentally. The thymus 
serves a pivotal role within the immune system by producing lymphocytes T-cells and B-cells. In 
a healthy individual the T-cells are non-reactive to self-cells, but if the thymus fails to eliminate 
the self-reactive T-cells an autoimmune disorder, such as MS may commence. Peripheral 
immunological tolerance is the primary mechanism that maintains a balance between immune 
reactions toward self and non-self antigens. Dysregulation of immune self-antigens is considered 
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key to understanding autoimmune disorders. Regulatory T cells (TREG) are now understood to be 
a major component in CNS autoimmune inflammation. Deletion of TREG cells leads to 
spontaneous autoimmune disease in mice, while an elevation prevents the progression of EAE 
induction.  Maintenance of peripheral tolerance has been correlated with amplified TREG cells 
and protects against EAE progression. TREG cells are classified based on the cytokine secreted 
and surface phenotype (Zozulya et al., 2008). The most well understood type is nTREG cells, 
which are characterized as CD4+CH25+TREG lymphocyte cells. These cells develop in the thymus 
and are responsible for the expression of interleukin 2 (IL-2) and transcription factor FOXP3 
(Zozulya, Wiendl et al. 2007). FOXP3 regulatory T cells produce TH3 regulatory cells which 
proceed to recruit anti-inflammatory cytokine TGF-B (McFarland et al. 2007). These studies 
found that an increase in TREG levels is associated with preventing axonal damage characteristic 
with autoimmune diseases, therefore serving a protective role. Impaired 
CD4+CH25+FOXP3+TREG cells may explain the intolerance for self-antigens and increased 
autoimmunity susceptibility. In support of this claim, Veken et al., (2014) found that impairment 
of FOXP3 was correlated with patients in the relapse-remitting phase of MS.  
 Later work by Dieckmann et al., (2007) found that TREG can be identified and quantified 
in peripheral blood of healthy and diseased humans. This work exhibited that CD4+CH25+TREG 
cells isolated from MS patients are morphologically impaired, yielding impairments in the 
thymus (Zozulya, Wiendl et al., 2008).  Impairment of CD4+CH25+TREG cells transforms the 
thymus’s efficiency in eliminating self-reactive T-cells. This loss of function could be a primary 
route in the initiation of MS self-reactivity.  
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CUPRIZONE INDUCED DEMYELINATION 
 Demyelination induced via CPZ administration is attributed to the formation of 
megamitochondria in mature OLGs following a 3 week 0.2% CPZ supplemented diet (Praet et 
al., 2014). However, CPZ exhibits no effect on microglia, astrocytes, and OPCs (Praet et al., 
2014; Matsushima et al., 2001).  CPZ administration inhibits Complex IV activity and uncouples 
oxidative phosphorylation. While complexes I, II, and III are uninhibited by the treatment, the 
effect on Complex IV is significant. As the levels of reactive oxygen species (ROS) and reactive 
nitrogen species (RNS) increase, oxidative stress leads to the formation of the 
megamitochondria, making the OLGs vulnerable to degradation (Acs et al., 2013). In addition to 
an increased vulnerability, ROS free radicals can then amplify the damage via lipid peroxidation 
by oxidizing the OLGs high concentration of intracellular Fe3+ into Fe2+. The remaining Fe2+ 
then proceeds to initiate the degradation of lipid membranes (Praet et. al. 2014).  
 Increased concentrations of ROS and RNS will, in addition to causing the uncoupling of 
the electron transport chain, disrupt the myelin sheath via endoplasmic reticulum (ER) stress. 
The stress on the ER reduces mRNA transcription and translation in order to reduce an 
accumulation of misfolded proteins. Immediately following this down-regulation, myelin 
protein-related mRNA production is quantifiably reduced during CPZ treatment (Arnett et al., 
2003).  While undergoing CPZ treatment the misfolded proteins that are released from the ER 
accumulate and initiate an unfolded protein response (UPR), which leads to an efflux of calcium 
and subsequent OLG death. The mitochondrial enlargement caused by increased ROS/RNS 
levels may be viewed as a protective measure to reduce oxidative stress (Wakabayashi et al., 
2002). This claim is supported by observations that after CPZ treatment termination the 
mitochondria in mature OLGs regain normal morphology and function (Praet et al., 2014).  
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 While CPZ induced demyelination is in effect, oligodendrocyte progenitor cells are 
continuously attempting to remyelinate by producing OLGs that may proliferate and repair 
axons. Meanwhile the OLGs that are synthesized are vulnerable to protein misfolding and cell 
death. For studies that are attempting to understand potential therapeutics, it is crucial to 
exclusively produce demyelination with no underlying attempts of remyelination. A 
CPZ/rapamycin model would yield complete demyelination with no underlying remyelination 
and would exclude any OPC’s attempt to differentiate into mature OLGs during demyelination. 
Such a model has yet to be universally approved by the scientific community; however recent 
studies have found that intraperitoneal injection of rapamycin can successfully inhibit production 
of OPCs when given in conjunction with CPZ treatment. This combination of treatments can 
allow for complete demyelination following a longer remyelination period (Sachs, Bercury, et al. 
2014).  
 Current literature indicates that healthy OPCs are continuously proliferating in an attempt 
to differentiate into OLGs throughout CPZ administration. Utilization of CPZ limits 
differentiation of OLGs, but does not prevent ongoing remyelination during the demyelination 
phase of the study. Oxidative stress during treatment also reduces ATP production and the 
degree of irregularity within the CPZ model yields a broad mixture of cell responses. A recent 
2014 study by Sachs et. al (2014) reported promising results using CPZ in conjunction with 
intraperitoneal injections (IP) of rapamycin in which the treatment plan yielded greater 
demyelination and slowed remyelination. Rapamycin inhibits astrocytes, which is a signaling 
factor for microglia, furthermore inhibiting active myelination via inhibition of Akt/mTOR 
signaling pathway. Therefore combined administration of CPZ/rapamycin exhibits significantly 
greater demyelination compared to CPZ treatment alone. 
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PREVIOUS APPLICATIONS OF RAPAMYCIN  
 The mammalian target of rapamycin (mTOR) was discovered in the 1970’s in a soil 
sample obtained from the Polynesian island of Rapa Nui, which exhibited novel antifungal 
activity. It was named rapamycin in order to not only allude to its place of discovery, but its 
remarkable characteristics as well.  Now, a widely utilized immunosuppressant, it has a variety 
of uses, including post-transplantation therapy, prevention of restenosis following angioplasty, 
and as a potential treatment for certain cancers.  
 The physical target of rapamycin is the mTOR pathway that functions in response to 
hormonal and nutrient cues as a controller of cell growth and metabolism. There are two main 
complexes mediated through mTOR. mTORC1 (complex 1) is bound by rapamycin through 
FK506-binding protein and directly decreases activity. Contrariwise, rapamycin indirectly 
inhibits mTORC2 (complex 2). Although, this form of inhibition takes place during chronic 
exposure and is primarily thought to contribute to metabolic control (Johnson et al., 2013).  
 mTORC1 can be controlled by a plethora of cues. Activation of the pathway is mediated 
by insulin-like growth factor-1 (IGF-1) and other growth factors such as Akt and PI(3)K 
signaling. Repression is mediated by AMP-activated kinase (sensor for cellular energy), dietary 
restrictions, and prolonged hypoxia (Johnson et al., 2013). mTORC1 activation increases protein 
synthesis through two substrates: ribosomal protein S6 kinase (S6Ks) and eukaryotic translation 
initiation factor 4E-binding protein 1 (4E-BP1) (Johnson et al., 2013). Activation of mTORC1 
leads to the phosphorylation of S6Ks and 4E-BP1, ultimately leading to mTOR dependent gene 
transcription, protein synthesis/lipid biosynthesis, and cell growth (Kim, et al., 2008; Harrison et 
al., 2009). This pathway also inhibits the degradation of autophagy. With age, this repression of 
autophagy is increasingly inhibited resulting in an accumulation of damaged protein aggregates 
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and degeneration of the mitochondria, both of which can contribute to age related cellular 
dysfunctions (Johnson et al., 2013; Neff et al., 2013).  
 Previous studies have additionally indicated that mTOR signaling regulates the aging 
process and are associated with an extension of lifespan (Fang et al., 2013; Johnson et al., 2013). 
Deletion of S6K in yeast (S. cerevisiae), mutations in mTOR pathway and mutations in 
mTORC1 pathway of fruitfly (Drosophila melanogaster) result in an increase in lifespan. 
Inhibition of mTOR and mTORC1 components can be mediated through rapamycin. Previous 
studies have confirmed that introduction of rapamycin in multiple organisms extends their 
lifespan, including yeast, nematodes, fruitflies, and mice (Johnson et al., 2013).   
 Similar effects of longevity are observed with dietary restrictions. This comes as no 
surprise because the mTOR path functions in response to nutrient and growth cues. Inhibition of 
mTOR via rapamycin or dietary restrictions would reduce cellular growth and reduce cues for 
aging. These findings have been confirmed in other studies as well. For example, Colman et al., 
(2009) found that dietary restriction reduces the likelihood of developing cancer, cardiovascular 
disease, diabetes, and brain atrophy in the rhesus macaque monkey. This study suggests that 
rapamycin supplementation would have similar beneficial effects on age-related decline.  
 IGF-1 promotes the mTOR pathway via Akt/PI3K signaling (Narayanan et al., 2009), 
therefore inhibition of mTOR via rapamycin would reduce IGF-1 and would reduce age-related 
pathologies. A reduction of IGF-1 would promote the normally inhibited autophagy, further 
removing damaged organelles and macromolecules from the cytoplasm, therefore promoting 
longevity (Johnson et al., 2013). 
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RAPAMYCIN PARADOX 
 Many studies have pointed towards the remarkable benefits of rapamycin, so why has this 
immunosuppressant agent not been utilized clinically to reduce aging in humans? Other studies 
have highlighted the altered metabolic effects of rapamycin. Fang, et al., (2013) demonstrated 
detrimental metabolic effects of rapamycin following IP supplementation to C57BL/6 mice, 
therefore exhibiting a paradox of the improved lifespan theory. Acute rapamycin treatment 
inhibits mTORC1, but longer treatment induces a chronic and systemic reaction that effects 
mTORC2 (Sarbassoc et al., 2006). Detrimental effects included insulin resistance, 
hyperlipidemia, and glucose intolerance. Interestingly, these negative effects were only observed 
2 weeks into the treatment. The organism’s pancreatic volume was also reduced and the liver 
was enlarged after 2 weeks of treatment, but after 20 weeks organ sizes were back to normal. In 
conjunction with this, 2 weeks of treatment was characterized by a 2.5 fold increase in insulin, 
induced glucose intolerance and insulin resistance. Yet, around 6 weeks there was a transition 
phase in which the mice exhibited an improved metabolic state. After 20 weeks of a prolonged 
treatment, the mice proceeded from being insulin resistant to having enhanced insulin sensitivity.  
 Along with the improved insulin sensitivity, there was also an increase in metabolism and 
in efficiency of oxygen consumption. All of these observed changes suggest that rapamycin 
initially prompts a negative effect, yet after 6 weeks a clear transition takes place and by 20 
weeks of treatment, it supports the potential effects of longevity (Fang et al., 2013).  
 Rapamycin’s beneficial effects are exhibited following a significant period of treatment. 
Therefore utilization of the immunosuppressant characteristics could be beneficial to a MS 
model if utilized within the 6 week (0.2% CPZ) treatment timeframe. Another important 
consideration is the effect rapamycin has on inflammation. Inflammation is associated with a 
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large variety of age-related disorders and hyperactivation of the mTOR pathway is associated 
with inflammation (Johnson et al., 2013). In assessment of remyelinating therapeutics, it would 
be beneficial to produce ample demyelination unaccompanied by ongoing remyelination, 
followed by recovery from CPZ/rapamycin administration by allowing remyelination. While 
CPZ lacks the inflammatory response associated with MS, addition of rapamycin yields a model 
that is ideal for assessing remyelination therapeutics by exhibiting the most complete and 
reproducible demyelination. Ample demyelination would allow full assessment and 
quantification of therapeutics that can alter and promote remyelination. 
 In summary, our present understanding of rapamycin is that it exhibits a plethora of 
reversible negative systemic effects after 2 weeks of treatment. After 6 weeks of treatment, a 
metabolic shift takes place towards an improved state from baseline. Finally, by 20 weeks of 
treatment, several of the initially detrimental effects transition towards progressively improved 
states from baseline. In the context of CPZ treatment, the time frame under investigation is the 
first 6 weeks, during which time rapamycin effectively prevents remyelination attempts in the 
presence of an acute demyelinating event. Therefore the dual CPZ/rapamycin provides a novel 
model of reversible demyelination that can be used to develop new therapies to promote 
remyelination. 
 
RAPAMYCIN: INHIBITOR OF ACTIVE REMYELINATION  
 A major signaling pathway regulating myelination is the Akt/mTOR pathway. Chronic 
inhibition of this pathway in young wild type (WT) mice leads to reduction of myelination 
(Narayanan et al., 2009). The reduction in myelination that immediately follows inhibition is not 
recorded in WT mice after six to twelve weeks of age, demonstrating that in normal mice 
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myelination is no longer controlled by this major signaling pathway around this age. This 
suggests that remyelination is regulated by the Akt/mTOR pathway in adult mice (Narayanan et 
al., 2009).  
 It has been suggested that Akt signaling is a regulator of the amount of myelin generated 
per oligodendrocyte and has little control of the number of OLGs and OPCs (Flores et al., 2009). 
Hence, it is reasonable to hypothesize that with the use of rapamycin there would be a significant 
reduction in the translation of myelin mRNAs such as, MBP, MOG, and myelin associated 
glycoprotein (MAG). Inhibition of mTOR signaling by rapamycin has been effective in the 
inhibition of Akt/mTOR in studies using mouse models of MS in vivo (Narayanan et al., 2009).  
 More importantly, inhibitors to mTOR signaling have been previously used in many 
cancer therapies and neurological disorders (Narayanan, 2009). As discussed earlier, recent 
studies have suggested that the use of CPZ/rapamycin yields greater demyelination due to 
rapamycin’s ability to inhibit the ongoing OPC’s attempt to remyelinate during the 
demyelination phase (Sachs et al., 2014). The combined use of both components allows for more 
complete investigation of the remyelination process and analysis of clinically reflective 
therapeutics from the elongated remyelination phase. Remyelination in adult mice is controlled 
by the Akt/mTOR pathway and continuous expression allows for maintenance of OLGs (Flores 
et al. 2000). This pathway of activation is exhibited in Figure 1 below. OLGs are also more 
sensitive to rapamycin during active myelination (Narayanan et al., 2009). Long-term rapamycin 
treatment alone promotes longevity by inhibiting the mTOR pathway, but short-term inhibition 
of this pathway also inhibits OPCs from differentiating into OLGs. It would be reasonable to 
hypothesize that the use of rapamycin would inhibit the Akt/mTOR signaling pathway, leading 
to inactive differentiation of OPCs and an overall reduction in myelin protein translation. 
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Normal mTOR signaling pathway 
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Cell growth and 
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---|  
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Oligodendrocytes  
(OLGs) 
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Figure 1: Exhibits the mTOR signaling pathway with and without rapamycin inhibition.  
 
DUAL TREATMENT: CUPRIZONE AND RAPAMYCIN  
 CPZ treatment alone exhibits non-immune mediated demyelination with continual 
remyelination. Rapid remyelination ensues immediately after treatment is discontinued, with 
substantial remyelination after 6 weeks of treatment (Matsushima et al., 2001). Ongoing and 
rapid remyelination following termination is promoted by the progressing OPC surge that is 
continuously attempting to differentiate into mature OLGs. The OPC surge coincides with an 
infiltration of microglia, macrophages, and astrocytes, with maximum demyelination at 4-5 
weeks (Praet et al., 2014; Matsushima et al., 2001).  
 In the assessment of models aiming to understand therapeutics, it would be most 
beneficial to completely separate the two phases of myelination into solely demyelination, 
followed by remyelination. From our current understanding of rapamycin, this may in fact be 
possible. Utilization of rapamycin in conjunction CPZ would prevent ongoing remyelination 
characteristically seen with CPZ, therefore allowing greater demyelination. Inhibition of the 
differentiating OPC pool would also yield slower remyelination once treatment is removed. 
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While the CPZ and EAE animal models can mimic the demyelinating effects of MS, the 
combined CPZ/rapamycin treatment would allow for better understanding of therapeutics due to 
the ability to separate the demyelination and remyelination phases.  
 A recent study by Sachs et al., 2014 utilized rapamycin treatment during the 6 week CPZ 
induced demyelination phase. Investigators of the study used 0.3% CPZ in combination with IP 
injections 5 days a week, which consisted of rapamycin (10mg/kg) dissolved in a vehicle 
solution. The results of the study showed that the subjects experienced greater demyelination and 
an elongated window of remyelination compared to the CPZ and EAE models. This 
remyelination window provides an immense benefit for future therapeutic assessments (Sachs et 
al., 2014).   
 In conclusion, with the use of both compounds, Akt/mTOR signaling is successfully 
inhibited, therefore suppressing any attempt of OPCs to differentiate. Once CPZ treatment is 
halted, mitochondria regain normal morphology and function (Praet et al., 2014).  
 
DUAL TREATMENT: MACROPHAGE/MICROGLIAL RESPONSE 
 MS pathology is characterized by the presence of a leaky blood-brain-barrier (BBB), 
allowing for the infiltration of inflammatory cells, including self-reactive T-cells. In contrast to 
this infiltrated immune response, demyelination induced via CPZ treatment occurs in the 
presence of an intact BBB and without substantial immune response involving B and T cells. 
This is confirmed by the study by Praet et al., (2014) in which RAG-/- mice (devoid of B and T 
cells) exhibit similar demyelination to WT mice, confirming lack of B and T cell involvement 
during CPZ treatment.  
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 Therefore, the only immune cells present in the demyelinated regions are resident 
microglia and macrophages. The BBB does not permit their transport and the source of their 
infiltration is unknown (Matsushima & Morell, 2001). The exact contribution may vary during 
demyelination and remyelination. Their respective roles during de-/remyelination is not fully 
understood. Previous studies have shown that they are found in the highest concentration within 
the lesions themselves, and this localization could be a strategy to aid in remyelination, as one of 
their primary roles is to clean myelin debris. 
 Interestingly, around 3 weeks of CPZ treatment an elevated infiltration of 
microglia/macrophages coincides with an increase in OPCs and astrocytes (Praet et al., 2014). 
Perhaps it would be accurate to propose that rapamycin supplementation could be preventing 
OPC differentiation via inhibition of infiltrating microglia/macrophages.  
 Xie et al., (2014) tested this theory by injecting rapamycin into the lateral ventricles of 
rats, 6 h after a focal stroke was induced. In this study, the goal was to understand the role of 
mTOR signaling in post-stroke neuroinflammation. Results from the study revealed that IP 
treatment inhibited polarization toward pro-inflammatory macrophages (M1) and shifted the 
immune response towards anti-inflammatory macrophages (M2). However, this shift towards M2 
macrophages is not a direct effect of rapamycin. The shift towards M2 macrophages was further 
amplified by a surge of TREG cells, which indicated that IP rapamycin elevates anti-inflammatory 
TREG cells before proceeding to shift the microglia/macrophages towards M2 anti-inflammatory 
response. These findings are further confirmed by the macrophage and microglial M1 response 
via TREG devoid cells.  
 At 3 weeks of CPZ treatment, remyelination is ongoing as the OPC surge coincides with 
microglia/macrophage infiltration. However, CPZ treatment supplemented with IP injections of 
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rapamycin may hinder OPC differentiation, providing greater demyelination compared to CPZ 
treatment alone.  
 Furthermore, the role of TREG cells is confirmed by a recent study that enriched units of 
whole blood from MS patients with CD25+ cells. The cells cultured with expanded with 
rapamycin exhibited strong suppressor activity with a 91.4% increase in CD4+ cells. These 
findings revealed that an addition of rapamycin could be potentially applied clinically, as these 
cultures exhibited increased purity and potency of cells with the phenotype and function of TREG 
cells (Keever-taylor et al., 2007). However, it should be noted that the sample size included only 
3 MS patient’s blood samples, which has limited applicability to a broader range of patients and 
in-vivo applications.    
 
DUAL TREATMENT: ASTROCYTES  
 Astrocytes function within brain homeostasis and immunity. As the most abundant cell in 
the CNS, their primary role is to support and regulate neural tissue (Mayo et al., 2012). As 
discussed earlier, CPZ treatment is accompanied by an intact BBB. In the attempt to model MS, 
the maintenance of the BBB fails to reflect the immune component of the demyelinating disease. 
While this helps to separate events related to demyelination and remyelination, it also bypasses 
considerable immune complexities that are clinically and therapeutically relevant (Matsushima & 
Morell, 2001).  
 Astrocytes help to maintain the BBB and their activation is associated with demyelinating 
disorders. Chemokines secreted from astrocytes attract immune cells from blood’s peripheral 
immunity and resident CNS glial cells. The peripheral immune cells include T cells, monocytes, 
and dendritic cells; resident CNS cells include microglia and OPCs (Mayo et al., 2012).  
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 CPZ treatment, utilizing C57BL/6 mice exhibits gliosis around 3 weeks, with a peak 
surge around 4-6 weeks. This gliosis is related to the increased number of 
microglial/macrophages and astrocytes (Gudi et al., 2014). These findings are congruent with 
work by Komely et al., (1992) in which mice treated for 8 weeks with CPZ exhibited IGF-1 
positive astrocytes. A major function of microglia is to stimulate astrocytes to increase the 
release of chemokines to promote remyelination. After 3 weeks CPZ treatment, OPCs are 
recruited and differentiate into OLGs. Studies have suggested that this ongoing remyelination 
may be indirectly facilitated by microglial and astrocytic release of IGF-1.  
 Within the CPZ model, OPCs are continually attempting to differentiate into OLGs via 
astrocytes/microglial stimulation. Rapamycin treatment alone exhibits an opposing reaction. 
Intraperitoneal injections (IP) of rapamycin to post-stroke rats revealed that reactive astrocytes 
were inhibited and neurons were protected post-stroke (Xie et al., 2014). Previous studies have 
exhibited similar findings, in which rapamycin completely inhibited mTOR phosphorylation 
(Lisi et al., 2011). Astrocyte activation is dependent on the mTOR signaling pathway and is 
sensitive to inhibition via rapamycin (Xie et al., 2014). Furthermore, inhibition of astrocytes via 
rapamycin could be a possible route of increased demyelination associated with CPZ/rapamycin 
administration. A reduction in astrocyte recruitment would lead to a reduction in microglia and 
OPC recruitment (Mayo et al., 2012). Therefore, rapamycin may function to inhibit astrocyte 
recruitment, which would additionally inhibit OPC differentiation and result in more complete 
demyelination when combined with CPZ administration  
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DUAL TREATMENT: MAST CELLS  
 Mast cells are derived from bone marrow and reside in the CNS where they proliferate in 
response to various cytokines and growth factors. Interestingly, these cells are directly observed 
within regions of demyelination. (Skaper et al., 2012). Phosphoinositide 3-kinase (PI3K) 
signaling regulates mast cell production and homeostasis (Kim et al., 2008). PI3K activates 
mTORC1 signaling, furthering mast cell development and cell growth associated with the mTOR 
pathway.  
 Previous studies have also suggested that mast cells can rapidly cross and diminish the 
integrity of the BBB further promoting infiltration of immune cells (Mayo et al., 2012). Such 
findings are confirmed by EAE immune mediated demyelination, in which organisms devoid of 
mast cells exhibit decreased BBB permeability. Inhibition of mTORC1 yields reduced cell 
growth and mast cell infiltration. Rapamycin used in conjunction with CPZ inhibits PI3K 
signaling towards mast cell development via indirect inhibition of mTORC1 (Kim et al., 2008).   
 
DUAL TREATMENT: INSULIN-LIKE GROWTH FACTOR-1 
 An increase in OPCs and microglia/macrophages at 3 weeks of CPZ treatment coincides 
with an increase in insulin-like growth factor-1 (IGF-1) (Komoly et al., 1992). In order to release 
IGF-1, there must be a supportive environment allowing for the remyelination to begin. It comes 
as no surprise, due to their involvement at other stages, that microglia and astrocytes are 
responsible for OPC recruitment (Matsushima & Morell, 2001). Previous studies exhibited 
similar findings, in which mice treated with CPZ for 8 weeks contained IGF-1 positive astrocytes 
(Komoly et al., 1992).  
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 Activation of mTOR1 is promoted by IGF-1, leading to an increase in mRNA translation 
and protein synthesis via ribosomal subunit 6S (Johnson et al, 2013; Gudi et al., 2014). As 
discussed earlier, active myelination is dependent on the Akt/mTOR pathway (Narayanan, 2009), 
which can be modulated via rapamycin supplementation. OPC differentiation during CPZ 
treatment can be inhibited by rapamycin, yielding more complete demyelination during CPZ 
induced demyelination.  
 
BENEFITS OF UTILIZING THE DUAL TREATMENT 
 In previous trials, rapamycin has been introduced to the organism orally. However, recent 
studies have utilized IP injections of rapamycin to mimic the pathophysiology of MS. Recent 
studies by Sachs et al, (2014) and by Narayanan et al, (2009) introduced the dual CPZ/rapamycin 
treatment. Both groups administered 0.3% cuprizone and IP injections of rapamycin to eight-
week old C57BL/6J male mice.  
 After only 6 weeks of CPZ/rapamycin treatment, there is significantly more 
demyelination compared to CPZ and EAE models, with the highest proportion of demyelination 
occurring in caudal regions of the CC, hippocampus, and superior cerebellar peduncles. It would 
be appropriate to hypothesize that effective inhibition of the Akt/mTOR pathway was achieved. 
This claim can be confirmed via inactivation of the mTOR pathway following in-vivo treatment 
utilizing rapamycin. After 4 weeks of treatment MOG reactivity was similar in both the CPZ 
group and the CPZ/rapamycin group. Increased reactivity of MOG correlates with remyelination, 
as it is a glycoprotein important in the myelination process (Sachs et al., 2014).  However, by 6 
weeks of treatment MOG reactivity was barely detectable (4%) in the CPZ/Rapamycin and 
therefore was significantly more reduced in the CPZ/Rapamycin group, this demonstrates that 
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administration of rapamycin during CPZ treatment reduces ongoing OPC differentiation into 
mature OLGs. Inhibition of differentiation is important because it allows complete separation of 
both de-/remyelination phases, which provides a clearer route to assess whether certain 
therapeutics are effecting demyelination and/or the remyelination phase. Tagge et al., (2016) 
demonstrated that CPZ induced demyelination yields complex spatio-temporal patterns of de-
/remyelination in the CC. Although the mechanisms behind variable demyelination throughout 
the CC are unknown, it is possible that certain regions are either less susceptible to 
demyelination, or are repaired more quickly than others. A model, such as CPZ/rapamycin may 
offer reliable patterns of pathology that would be beneficial in providing a more complete 
understanding of the biological processes responsible for demyelination and repair that will 
ultimately help identify and study new therapeutic approaches. 
 Remyelination is significantly slowed following removal of the dual treatment, whereas 
after CPZ administration, remyelination of axons within the corpus callosum is evident one week 
after termination of treatment. Maximum remyelination was recorded after five weeks of 
recovery in CPZ-only mice. In contrast, the CPZ/rapamycin treated mice had significantly less 
remyelination compared to CPZ-only mice after 5 weeks of recovery. To build upon this claim, 
the CPZ/rapamycin group was comparably slower in the attempt to remyelinate compared to the 
control group.  However, this value increased slowly. Towards the end of 7 weeks off treatment, 
the CPZ/rapamycin mice still had significantly less myelination compared to the CPZ-treatment 
group. (Sachs et al., 2014).  
 The promotion of demyelination and slowed remyelination provided by rapamycin can be 
attributed to its ability to inhibit any immune or neuroglial cues that would normally lead to 
remyelination. These include the ability to inhibit microglia and macrophage infiltration 
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associated with CPZ treatment alone. As discussed earlier, an OPC surge coincides with 
microglia and macrophage levels; however rapamycin utilizes TREG cells by polarizing microglia 
and macrophages towards M2 anti-inflammatory response. Research by Keever-Taylor et al., 
(2007) provided evidence that rapamycin cultured with peripheral blood samples of MS patients 
selectively inhibits auto-reactive T-cells and spares protective TREG cells. It may be possible that 
while rapamycin treatment alone is exhibiting an anti-inflammatory response, the slowed 
remyelination associated with dual in mice could be an indirect effect of rapamycin selectively 
sparing protective TREG.  
 Along with selectivity of TREG cells, rapamycin is able to inhibit astrocyte recruitment 
during CPZ-treatment. Normally, astrocytic migration is followed by infiltration of microglia 
and OPCs. Inhibition of astrocytes, microglia, and OPCs migration suggest that rapamycin 
successfully inhibits any attempt of ongoing remyelination during CPZ-treatment, further 
providing ample demyelination compared to the CPZ-treatment group. Figure 2 highlights the 
fluctuating cellular interactions during CPZ treatment. Note that the astrocytes and OPC surges 
at week 4 coincide. Astrocytes are dependent on the Akt/mTOR pathway; following inhibition 
via rapamycin I expect to see a coinciding reduction of OPCs, resulting in a decline of new 
mature OLGs. 
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Figure 2: Summary of cellular trends during acute demyelination, followed by removal from 
CPZ treatment. Diagram was adapted from Mason et al., 2000.  
 
 The CPZ model exhibits incomplete demyelination and ongoing remyelination during 
CPZ-administration. Following CPZ/rapamycin treatment, there is a decrease in expression of 
MAGs, OPC differentiation into mature OLGs, and a slowed remyelination phase. The changes 
accompanied by rapamycin treatment allow for the assessment of separate demyelination and 
remyelination phases. The ability of CPZ/rapamycin to significantly demyelinate specific regions 
of the CC yields a model to investigate remyelinating therapeutics. Figure 3 outlines a treatment 
timeline utilizing CPZ compared to the benefit of the proposed CPZ/rapamycin treatment.  
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Cuprizone Treatment (0.2%) Week  
Current Understanding of Cuprizone 
Treatment (0.2%) + Rapamycin 
Microglia and Macrophage levels increase 
1 
Rapamycin inhibits the surge of Microglia, 
Macrophage, IGF-1, Astrocytes 2 
Microglia and Macrophage levels increase, 
myelin genes for MBP, MAG, CAG reduced 3 
Microglia, Macrophage, IGF-1, Astrocytes 
surge 4 
Complete loss of mature OLGs, 
Remyelination ~50% 5 
Remyelination ~ 90% 
6  
MOG activity declined, significantly greater 
demyelination, little-to-no-remyelination 
Microglia, Macrophage, IGF-1, Astrocytes 
levels decline 7 
Remyelination ~20%  
  
8 
  
9 
10 
11 
12 
13 Remyelination ~70% 
14 
  
15 
16 
Figure 3: Timeline of acute demyelination induced with CPZ versus CPZ in conjunction with 
rapamycin. Both treatments discontinued diets after 6 weeks. De-/remyelination was associated 
in the caudal regions of the corpus callosum (CC), hippocampus, and superior cerebellar 
peduncles, Axons were quantified with sections stained with para-phenylenedia-mine (PPD) 
(Sachs et al., 2014). 
 
 
POTENTIAL COMPLICATIONS OF DUAL TREATMENT: 
 Possible considerations for rapamycin use would be the transient detrimental effects it 
has on metabolism. These effects are only seen during the first 6 weeks of treatment and include 
insulin resistance, hyperlipidemia, and glucose intolerance (Fang et al., 2013). Narayanan et al., 
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(2009) noted that after 6 weeks of treatment there was a significant decrease in brain size and 
body weight. By the end of 6 weeks, a pivotal shift in the organism’s state took place. By 20 
weeks of IP rapamycin treatment, mice exhibited an improved metabolic profile and increased 
oxygen consumption compared to their baseline states (Fang et al., 2013).  
 
CONCLUDING REMARKS  
 Utilization of the CPZ model during therapeutic assessment is confounded by continuous 
attempts of OPCs to differentiate into OLGs during demyelination.  The dual CPZ/rapamycin 
model yields more complete demyelination and a slowed rate of remyelination. The significance 
of slowed remyelination is measurable, as CPZ treatment group yielded ample remyelination by 
6 weeks of recovery. Contrariwise, the CPZ/rapamycin group exhibited significantly less 
remyelination 6 weeks into treatment removal. The ample demyelination associated with dual 
treatment offers a novel route to investigate remyelinating therapeutics that may target specific 
regions of the caudal CC and superior cerebellar peduncles. 
 Multiple Sclerosis is a disease characterized by demyelination and extensive 
remyelination. The proposed CPZ/rapamycin model for MS could be more reliable during the 
assessment of therapeutics, due to the significant demyelination that is largely reversible and the 
elongated spontaneous remyelination window. Such a model has yet to be utilized in 
investigations for MS therapeutics and there is substantial reason to believe that this model may 
provide a reliable model for reversible demyelination and spontaneous remyelination. 
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